Does the circulating tumor cell count predict survival in metastatic hormone-sensitive prostate cancer?

By Lila Rouland | Published on November 10, 2025 | 3 min read


Metastatic hormone-sensitive prostate cancer (mHSPC) is a clinical entity in which combination therapies have significantly improved overall survival. However, despite these advances, interindividual variability in treatment response remains high, making it difficult to identify patients at high risk of progression.

Given this heterogeneity, circulating tumor cells (CTCs) are emerging as non-invasive blood biomarkers potentially predictive of clinical outcomes. While already validated in castration-resistant prostate cancer (mCRPC), their prognostic value in hormone-sensitive disease has yet to be established. This study aimed to assess the relationship between baseline CTC count and overall survival in patients with mHSPC enrolled in the phase 3 S1216 clinical trial.